Le livre est actuellement en rupture de stock
En savoir plus sur le livre
The study investigates the surge in mergers and acquisitions within the pharmaceutical industry, highlighting over 1,300 deals valued at approximately US$ 690 billion from 2000 to 2009. It emphasizes the largest transaction during this period, Pfizer's acquisition of Wyeth for US$ 66.7 billion in 2009. The research explores the motivations behind these significant mergers, particularly as responses to patent expirations, and examines their implications for drug innovation, reflecting on the broader public interest surrounding these transactions.
Achat du livre
Do Pharmaceutical Mergers Harm Drug Innovation?, Jan Schmidt
- Langue
- Année de publication
- 2015
- product-detail.submit-box.info.binding
- (souple)
Nous vous informerons par e-mail dès que nous l’aurons retrouvé.
Modes de paiement
Personne n'a encore évalué .